🔗 Share this article

While America undertakes sweeping revisions to its immunization schedules, an unexpected name has emerged unexpectedly: Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on coronavirus shots throughout the pandemic and has focused upon potential deaths following Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Health officials were set to reveal major changes to the childhood vaccination calendar in December, bringing the US with Denmark’s national calendar, it is understood – a major change that would put the US at odds with many the international standard with no evidence for benefit. This reveal has been pushed back until the next year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to head the center this year.

Consolidating Power at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain childhood immunization guidelines in the US to become more in line with Denmark, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

To date comments, she has kept her attention on immunizations – usually the domain of Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has no apparent background in drug development, regulation or management, which has been customary for past heads of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in running a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with legal statutes and the research of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who led the center have had.”

The drug center has an immense range of responsibilities at the agency, she emphasized.

“Many people just zeroes in on the new drug program, but the generic drug division clears thousands of generic medications. There’s a biosimilars program, OTC medication office and so forth, and all of those must be managed,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a major administrative component to the position, which supervises over 5,000 staff members. “It is a enormous management job, if you do it right,” the former official said.

Official Statement and Disputed Policies

When asked about questions about Dr. Høeg's qualifications and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary responded that the “inquiries stem from incorrect presumptions”.

“This background is consistent with the duties of her position,” the representative stated, pointing to the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a disputed one-day medication authorization process that allegedly worried her former heads. “How are these drugs being chosen for this voucher program? Who is making the choices?” Dr. Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent oversight of most medications, except for shots.”

Documented History on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if problematic, track record, some experts have noted. She published a study using non-validated crowd-sourced reports to assess the frequency of heart inflammation after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are riskier than they are.

Part of her “desired changes” for the new government included changing guidelines for new vaccines and halting “optional” vaccines, she said following the vote on a audio program. At the FDA, Dr. Høeg has reportedly suggested preventing young men from getting Covid vaccinations.

“She’s an all-around dogmatist who commences with her conclusions and tailors the evidence to fit the science in a highly misleading, dishonest manner,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|